EUVIMEDEUVIMED entdecken
Crossref

Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study

Dilsat Firat Arslan, Caner Civan, Mehmet Oner Sanli, Duygu Has Simsek, Meltem Ekenel, Mert Basaran, Selcuk Erdem, Faruk Ozcan, Serkan Kuyumcu, Yasemin Sanli

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8386-8393

DOI: 10.1007/s00259-026-08149-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 24.08.2026. Verfasst von Dilsat Firat Arslan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey. arslandf@istanbul.edu.tr. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Concurrent enzalutamide may upregulate PSMA expression and enhance the efficacy of [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). We evaluated outcomes of PSMA-RLT with and without concurrent enzalutamide in a real-world metastatic castration-resistant prostate cancer (mCRPC) cohort. METHODS: We retrospectively evaluated 208 mCRPC patients treated with [177Lu]Lu-PSMA-617 at a single institution between June 2015 and January 2026. Among them, 106 received concurrent enzalutamide and 102 without any concurrent androgen receptor pathway inhibitor. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), PSA50 response, pain response, and toxicity. RESULTS: Median OS was 20.0 months in the concurrent enzalutamide group versus 12.4 months in the no-ARPI group (log-rank p = 0.082). In multivariable Cox analysis, concurrent enzalutamide was not independently associated with OS (hazard ratio 1.15, 95% confidence interval 0.77-1.70; p = 0.493). This lack of independent association was confirmed in propensity-score adjusted analyses. PFS (7.1 vs. 6.1 months; p = 0.112), PSA50 response rates (57.5% vs. 47.1%; p = 0.130) and toxicity profiles were similar between groups. CONCLUSION: Concurrent enzalutamide during PSMA-RLT was not independently associated with improved OS or PFS in our cohort. The combination did not result in increased toxicity. Prospective studies are needed to further clarify the role of concurrent enzalutamide in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingLutetiumMaleHumansRetrospective StudiesNitrilesBenzamidesTreatment OutcomeAgedNeoplasm MetastasisMiddle AgedLigandsAged, 80 and overRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

EnzalutamideMCRPCPSMAProstate cancerRadioligand therapy

Substanzen

PhenylthiohydantoinenzalutamideNitrilesDipeptidesBenzamidesHeterocyclic Compounds, 1-RingLutetiumPSMA-617Lutetium-177Ligands

Autor:innen und Institutionen

  • Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey. arslandf@istanbul.edu.tr.
  • Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany.
  • Istanbul Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey.
  • Institute of Oncology, Department of Oncology, Istanbul University, Istanbul, Turkey.

Zitieren

APA

Arslan, D. F., Civan, C., Sanli, M. O., Has Simsek, D., Ekenel, M., Basaran, M., Erdem, S., Ozcan, F., Kuyumcu, S., & Sanli, Y. (2026). Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8386-8393. https://doi.org/10.1007/s00259-026-08149-x

Vancouver

Arslan DF, Civan C, Sanli MO, Has Simsek D, Ekenel M, Basaran M, et al. Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8386-8393. doi:10.1007/s00259-026-08149-x

BibTeX
@article{Arslan2026,
  author = {Arslan, Dilsat Firat and Civan, Caner and Sanli, Mehmet Oner and Has Simsek, Duygu and Ekenel, Meltem and Basaran, Mert and Erdem, Selcuk and Ozcan, Faruk and Kuyumcu, Serkan and Sanli, Yasemin},
  title = {Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8386--8393},
  doi = {10.1007/s00259-026-08149-x}
}
Kostenlos starten →